JP2020506946A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506946A5
JP2020506946A5 JP2019542502A JP2019542502A JP2020506946A5 JP 2020506946 A5 JP2020506946 A5 JP 2020506946A5 JP 2019542502 A JP2019542502 A JP 2019542502A JP 2019542502 A JP2019542502 A JP 2019542502A JP 2020506946 A5 JP2020506946 A5 JP 2020506946A5
Authority
JP
Japan
Prior art keywords
oxo
carboxamide
dihydropyridazine
chlorophenyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019542502A
Other languages
English (en)
Japanese (ja)
Other versions
JP7128826B2 (ja
JP2020506946A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/052627 external-priority patent/WO2018146010A1/en
Publication of JP2020506946A publication Critical patent/JP2020506946A/ja
Publication of JP2020506946A5 publication Critical patent/JP2020506946A5/ja
Application granted granted Critical
Publication of JP7128826B2 publication Critical patent/JP7128826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019542502A 2017-02-09 2018-02-02 がん治療のための2-ヘテロアリール-3-オキソ-2,3-ジヒドロピリダジン-4-カルボキサミド類 Active JP7128826B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17155406.6 2017-02-09
EP17155406 2017-02-09
EP17202882 2017-11-21
EP17202882.1 2017-11-21
PCT/EP2018/052627 WO2018146010A1 (en) 2017-02-09 2018-02-02 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2020506946A JP2020506946A (ja) 2020-03-05
JP2020506946A5 true JP2020506946A5 (enExample) 2021-03-11
JP7128826B2 JP7128826B2 (ja) 2022-08-31

Family

ID=61188789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542502A Active JP7128826B2 (ja) 2017-02-09 2018-02-02 がん治療のための2-ヘテロアリール-3-オキソ-2,3-ジヒドロピリダジン-4-カルボキサミド類

Country Status (39)

Country Link
US (2) US12522594B2 (enExample)
EP (1) EP3580211B1 (enExample)
JP (1) JP7128826B2 (enExample)
KR (1) KR102627266B1 (enExample)
CN (3) CN110678459B (enExample)
AU (1) AU2018217860B2 (enExample)
BR (1) BR112019016497A2 (enExample)
CA (1) CA3052718A1 (enExample)
CL (1) CL2019002255A1 (enExample)
CO (1) CO2019008684A2 (enExample)
CR (1) CR20190364A (enExample)
CU (1) CU24564B1 (enExample)
CY (1) CY1124484T1 (enExample)
DK (1) DK3580211T3 (enExample)
DO (1) DOP2019000206A (enExample)
EC (1) ECSP19057713A (enExample)
ES (1) ES2847162T3 (enExample)
GE (2) GEAP202115183A (enExample)
HR (1) HRP20210143T1 (enExample)
HU (1) HUE053191T2 (enExample)
IL (1) IL268469B (enExample)
JO (1) JOP20190193A1 (enExample)
LT (1) LT3580211T (enExample)
MA (1) MA47447B1 (enExample)
MX (1) MX2019009571A (enExample)
MY (1) MY198510A (enExample)
NI (1) NI201900085A (enExample)
PE (1) PE20191496A1 (enExample)
PH (1) PH12019501846A1 (enExample)
PL (1) PL3580211T3 (enExample)
RS (1) RS61401B1 (enExample)
SA (1) SA519402422B1 (enExample)
SG (1) SG11201907232XA (enExample)
SI (1) SI3580211T1 (enExample)
TW (1) TWI770113B (enExample)
UA (1) UA124507C2 (enExample)
UY (1) UY37606A (enExample)
WO (1) WO2018146010A1 (enExample)
ZA (1) ZA201905902B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017269870A1 (en) * 2016-05-25 2018-12-06 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
CN112724256B (zh) * 2019-10-28 2022-09-16 中国农业大学 一种高稳定性的磺胺类药物抗体hAb 4D11及其应用
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
US20230084899A1 (en) * 2019-12-16 2023-03-16 Bayer Aktiengesellschaft Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer
CN115244048A (zh) 2020-02-26 2022-10-25 捷豹治疗有限公司 可用于调节AhR信号传导的吡啶并嘧啶衍生物
WO2021194326A1 (en) * 2020-03-27 2021-09-30 Dong-A St Co., Ltd. Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114539221A (zh) * 2020-11-27 2022-05-27 苏州泽璟生物制药股份有限公司 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用
CN114685426A (zh) * 2020-12-28 2022-07-01 苏州泽璟生物制药股份有限公司 磺酰胺类抑制剂及其制备方法和应用
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
WO2023043753A1 (en) * 2021-09-14 2023-03-23 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders
AU2022369984A1 (en) 2021-10-20 2024-03-28 University Of Rochester Methods and compositions for rejuvenating cns glial populations by suppression of transcription factors
JP2025534283A (ja) 2022-10-03 2025-10-15 ジャグエーエイチアール セラピューティクス ピーティーイー リミテッド AhRシグナル伝達の調節に有用な化合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO2000009488A1 (en) * 1998-08-14 2000-02-24 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
JP2000119257A (ja) 1998-08-14 2000-04-25 Nippon Nohyaku Co Ltd ピリダジノン誘導体
US6358964B1 (en) 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
KR100770327B1 (ko) 2000-09-18 2007-10-25 에자이 알앤드디 매니지먼트 가부시키가이샤 피리다지논 및 트리아지논 화합물류 및 그들의 의약 용도
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
DE102004055998A1 (de) 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
EP1827445A2 (en) 2004-11-22 2007-09-05 King Pharmaceuticals Research and Development Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
EP1845081A4 (en) 2005-02-01 2009-03-25 Takeda Pharmaceutical amide
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
EP1953147A1 (en) 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
EP2023910B1 (en) 2006-05-03 2013-06-19 Symrise AG Ah receptor antagonists
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
DE102006054205A1 (de) 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
EP2518063B1 (en) 2006-12-21 2017-02-01 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
MX2010005519A (es) 2007-11-29 2010-06-11 Actelion Pharmaceuticals Ltd Derivados de acido fosfonico y su uso como antagonista del receptor p2 y12.
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP2860178B1 (en) 2008-10-31 2021-01-13 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
US20130338201A1 (en) 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
AU2011282776B2 (en) 2010-07-27 2014-06-12 Boston Medical Center Corporation Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2015143164A1 (en) 2014-03-19 2015-09-24 President And Fellows Of Harvard College Antimicrobial agents and screening methods
AU2017269870A1 (en) 2016-05-25 2018-12-06 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
JOP20190193A1 (ar) * 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
US11166959B2 (en) 2017-11-06 2021-11-09 Bristol-Myers Squibb Company Isofuranone compounds useful as HPK1 inhibitors
EP3713923B1 (en) 2017-11-21 2021-12-01 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
US11304946B2 (en) 2017-11-21 2022-04-19 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists
CA3082857A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
WO2019101642A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
CN113015526A (zh) 2018-09-19 2021-06-22 豪夫迈·罗氏有限公司 螺环2,3-二氢-7-氮杂吲哚化合物及其用途
EP3880198A4 (en) 2018-11-14 2022-08-10 The Broad Institute, Inc. ARYHYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS
KR20220045978A (ko) 2019-08-12 2022-04-13 바이엘 악티엔게젤샤프트 [1,2,4]트리아졸로[1,5-c]퀴나졸린-5-아민
WO2021074279A1 (en) 2019-10-16 2021-04-22 Bayer Aktiengesellschaft Spiro-fused tricyclic map4k1 inhibitors
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
EP4288437A1 (en) 2021-02-05 2023-12-13 Bayer Aktiengesellschaft Map4k1 inhibitors

Similar Documents

Publication Publication Date Title
JP2020506946A5 (enExample)
HRP20210143T1 (hr) 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidi za liječenje raka
RU2404164C2 (ru) Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
RU2497822C2 (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
RU2485114C2 (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
JP2017530185A5 (enExample)
JP2019537571A5 (enExample)
JP2019533694A5 (enExample)
JP2019518036A5 (enExample)
JP2016534023A5 (enExample)
JP2016528201A5 (enExample)
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
JP2021502387A5 (enExample)
RU2014147191A (ru) Амидопроизводные как блокаторы ttx-s
JP2010539110A5 (enExample)
JP2017511794A5 (enExample)
JP2017537948A5 (enExample)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2018505876A5 (enExample)
JP2018522847A5 (enExample)
JP2019532072A5 (enExample)
RU2019133530A (ru) ПРОИЗВОДНЫЕ АМИДА В КАЧЕСТВЕ БЛОКАТОРОВ Nav1.7 И Nav1.8
RU2018131766A (ru) 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета